February 2024
1. SHIRLEY M
   Etrasimod: First Approval.
   Drugs. 2024;84:247-254.
   

   >> Share

   
   September 2023
2. BLAIR HA
   Ritlecitinib: First Approval.
   Drugs. 2023;83:1315-1321.
   

   >> Share

   
   July 2023
3. GISBERT JP, Chaparro M
   Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
   Drugs. 2023 Jul 28. doi: 10.1007/s40265-023-01916.
   

   >> Share

   
   
4. VUYYURU SK, Shackelton LM, Hanzel J, Ma C, et al
   Targeting IL-23 for IBD: Rationale and Progress to Date.
   Drugs. 2023;83:873-891.
   

   >> Share

   
   
5. KEAM SJ
   Mirikizumab: First Approval.
   Drugs. 2023;83:1045-1052.
   

   >> Share

   
   May 2023
6. SKJELLERUDSVEEN BM, Skoie IM, Dalen I, Grimstad T, et al
   The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
   Drugs. 2023 May 23. doi: 10.1007/s40265-023-01888.
   

   >> Share

   
   March 2023
7. NUNEZ P, Quera R, Yarur AJ
   Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
   Drugs. 2023;83:299-314.
   

   >> Share

   
   November 2022
8. HOY SM
   Deucravacitinib: First Approval.
   Drugs. 2022;82:1671-1679.
   

   >> Share

   
   September 2022
9. PAIK J
   Correction to: Ozanimod: A Review in Ulcerative Colitis.
   Drugs. 2022 Sep 1. pii: 10.1007/s40265-022-01772.
   

   >> Share

   
   August 2022
10. PAIK J
    Ozanimod: A Review in Ulcerative Colitis.
    Drugs. 2022 Aug 22. pii: 10.1007/s40265-022-01762.
    

    >> Share

    
    July 2022
11. CRISPINO F, Grova M, Bruno EM, Monachino N, et al
    Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets.
    Drugs. 2022 Jul 28. pii: 10.1007/s40265-022-01750.
    

    >> Share

    
    June 2022
12. DHILLON S
    Carotegrast Methyl: First Approval.
    Drugs. 2022;82:1011-1016.
    

    >> Share

    
    August 2021
13. HANZEL J, Ma C, Vande Casteele N, Khanna R, et al
    Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Drugs. 2021 Aug 28. pii: 10.1007/s40265-021-01596.
    

    >> Share

    
    January 2021
14. HANZEL J, Ma C, Casteele NV, Khanna R, et al
    Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Drugs. 2021 Jan 5. pii: 10.1007/s40265-020-01460.
    

    >> Share

    
    March 2020
15. VUITTON L, Peyrin-Biroulet L
    Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease.
    Drugs. 2020;80:385-399.
    

    >> Share

    
    February 2020
16. KIM H, Alten R, Avedano L, Dignass A, et al
    The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
    Drugs. 2020;80:99-113.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share